Compassionate Psilocybin: Access Programs, Patient Eligibility & Clinical Context
An exploration of compassionate access frameworks for psilocybin — examining who qualifies, how clinicians apply for exemptions, the therapeutic setting requirements, and what patient outcomes data tell us about psilocybin's role beyond clinical trials.
Content Coming Soon
This resource is being prepared and will be available shortly.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar.
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. (2023). Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. International Journal of Mental Health Nursing, 32(4), 1025–1037. https://doi.org/10.1111/inm.13127
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
Shop Related Spores
Laboratory-grade Psilocybe cubensis spore syringes for microscopy research.